Back

Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Beating the odds: advances in cardiac amyloidosis treatment Clinical HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Assistant Professor Kevin Alexander

Stanford University School of Medicine, Palo Alto (United States of America)

6 More presentations in this session

Presentation thumbnail
Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study
Doctor L. Obici (Pavia, IT)
Abstract Slides Video
Presentation thumbnail
Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
Professor M. Fontana (London, GB)
Abstract Slides Video
Presentation thumbnail
Bioactive adrenomedullin as a predictor of clinical outcomes in cardiac transthyretin amyloidosis
Mr M. Mueller (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Beating the odds: advances in cardiac amyloidosis treatment

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
thumbnail
Congress Presentation
Acoramidis leads to clinically meaningful improvements from baseline in NT-proBNP and 6-minute walk distance in patients with transthyretin amyloid cardiomyopathy: observations from ATTRibute-CM
thumbnail
Congress Presentation
Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources